BioVie Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-17.43	-17.54	-32.12	-50.26	-26.08	-130.25
Depreciation & Amortization	0.23	0.23	0.23	0.23	0.23	0.23
Other Amortization	-	0.01	0.11	0.17	0.1	-
Loss (Gain) From Sale of Investments	-	-	-0.22	-	-	-
Stock-Based Compensation	2.32	2.47	4.66	6.38	6.19	3.02
Other Operating Activities	0.06	0.2	-0.51	3.5	-2.18	116.53
Change in Accounts Receivable	-0.2	-2.1	-	-	-	-
Change in Accounts Payable	1.54	-1.39	0.11	1.03	1.45	-0.26
Change in Other Net Operating Assets	-0.85	-0.91	-0.2	-1.3	1.3	0.28
Operating Cash Flow	-14.32	-19.03	-27.95	-40.25	-18.99	-10.45
Investment in Securities	-	-	14.53	-14.3	-	-
Investing Cash Flow	-	-	14.53	-14.3	-	-
Short-Term Debt Issued	-	-	-	-	-	0.44
Long-Term Debt Issued	-	2.9	-	-	14.61	-
Total Debt Issued	2.9	2.9	-	-	14.61	0.44
Short-Term Debt Repaid	-	-	-	-	-	-1.82
Long-Term Debt Repaid	-	-5.85	-10	-	-	-
Total Debt Repaid	-	-5.85	-10	-	-	-1.82
Net Debt Issued (Repaid)	2.9	-2.95	-10	-	14.61	-1.39
Issuance of Common Stock	7.56	15.67	27.8	55.37	18.51	16.31
Financing Cash Flow	10.46	12.73	17.8	55.37	33.12	14.93
Net Cash Flow	-3.86	-6.3	4.38	0.82	14.13	4.47
Cash Interest Paid	0.02	0.18	1.53	2.11	0.96	0.02
Levered Free Cash Flow	-8.28	-13.13	-18.78	-22.84	-8.77	-104.78
Unlevered Free Cash Flow	-8.27	-12.93	-17.08	-20.32	-7.52	-104.43
Change in Working Capital	0.5	-4.4	-0.09	-0.27	2.75	0.02

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q